sponsored
PatientsVille.com Logo

PatientsVille

Carvedil Medical Research Studies

Up-to-date List of Carvedil Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Carvedil Medical Research Studies

Rank Status Study
1 Unknown  Banding Ligation With Carvedilol Versus Carvedilol for the Prevention of First Bleeding
Condition: Variceal Bleeding
Interventions: Procedure: EVL + Carvedilol;   Drug: Carvedilol
Outcome Measures: patients with first bleeding;   patients with complications and mortality rates
2 Not yet recruiting Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32mg and Dilatrend Tablet 25mg
Conditions: Essential Hypertension;   Chronic Stable Angina;   Congestive Heart Failure
Interventions: Drug: Dilatrend SR capsule 32mg;   Drug: Dilatrend IR tablet 25mg
Outcome Measures: In the steady state Dilatrend SR Capsule 32mg and Dilatrend tablet 25mg AUCtau;   In the steady state Dilatrend SR Capsule 32mg and Dilatrend tablet 25mg AUCinf;   In the steady state Dilatrend SR Capsule 32mg and Dilatrend tablet 25mg Css,max;   In the steady state Dilatrend SR Capsule 32mg and Dilatrend tablet 25mg Css,min;   In the steady state Dilatrend SR Capsule 32mg and Dilatrend tablet 25mg Tss,max;   In the steady state Dilatrend SR Capsule 32mg and Dilatrend tablet 25mg t½;   Number of participants with adverse events
3 Not yet recruiting Carvedilol vs Band Ligation vs Combination Therapy for Primary Prophylaxis of Variceal Bleeding
Condition: Portal Hypertension Related to Cirrhosis
Interventions: Drug: Carvedilol;   Procedure: Variceal band ligation
Outcome Measures: Incidence of first variceal bleed;   Bleed-related mortality;   Overall mortality;   Recurrence of varices
4 Recruiting Trial of Carvedilol in Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Carvedilol;   Drug: Placebo
Outcome Measures: To determine whether Carvedilol treatment has a beneficial effect on episodic recall;   To determine whether Carvedilol treatment is associated with decrease in CSF levels of amyloid-beta oligomers
5 Recruiting Carvedilol for Psychostimulant Dependence
Conditions: Cocaine Dependence;   Cocaine Withdrawal
Interventions: Drug: controlled release Carvedilol;   Drug: Placebo
Outcome Measures: urine toxicology screens;   retention;   withdrawal symptoms;   orthostatic blood pressure
6 Unknown  RCT of Carvedilol Versus Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage
Condition: Portal Hypertension
Interventions: Drug: Carvedilol;   Procedure: Esophageal variceal band ligation
Outcome Measures: Variceal hemorrhage;   death
7 Unknown  Ischemia In Hemodialysed Patients: Ivabradine Versus Carvedilol
Conditions: Coronary Heart Disease;   Angina;   Hemodialysis
Interventions: Drug: Ivabradine;   Drug: Carvedilol
Outcome Measure: event-free survival
8 Unknown  Comparison of Effect of Carvedilol Compared To bISoprolol on cenTral Pulse Pressure in Hypertension (ARTIST) Study
Condition: Hypertension
Interventions: Drug: Carvedilol;   Drug: bisoprolol
Outcome Measures: Change in central pulse pressure (pulse pressure amplification);   Change in LV mass index Changes in LV diastolic functions (E/Em, left atrium volume) Changes in urinary albumin excretion, B-type natriuretic peptide (BNP), HOMA-IR, and oxidative stress (urinary 8-isoprostane). Change in ambulatory BP
9 Recruiting PAHTCH (Carvedilol)
Condition: Pulmonary Hypertension
Interventions: Drug: Carvedilol;   Drug: Carvedilol placebo
Outcome Measure: Biochemical abnormalities (HIF activation, NO synthesis, beta-adrenergic receptor recovery)
10 Recruiting Carvedilol + VSL#3 Versus Endoscopic Variceal Ligation for Primary Prophylaxis of Esophageal Variceal Bleeding in Cirrhosis.
Condition: Cirrhosis
Interventions: Drug: Carvedilol+VSL#3;   Procedure: Endoscopic variceal ligation
Outcome Measures: Development of first variceal bleeding;   Survival;   Requirement of liver transplantation;   Time to bleed;   Adverse events;   Development or worsening of complications of cirrhosis (ascites, encephalopathy, Hepato Renal Syndrome, Spontaneous Bacterial Peritonitis etc)
11 Recruiting Trial of Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis
Condition: Cirrhosis
Interventions: Drug: Carvedilol;   Drug: Placebo
Outcome Measures: the proportions of patients who develop esophageal varices at 1 year in each group.;   complications of cirrhosis (ascites, hepatic encephalopathy, SBP),;   Number of patient dying in a period of one year;   Number of patients needing discontinuation of therapy due to adverse effects.
12 Unknown  Coreg CR, Blood Vessel Stiffness and Blood Vessel Function
Conditions: Endothelial Function;   Diabetes Mellitus;   Hypertension
Interventions: Drug: Carvedilol;   Drug: metoprolol extended release
Outcome Measure: Effect of Coreg CR compared to Toprol XL on endothelial function, vascular compliance, and parameters of oxidative stress from time of randomization to study drug termination
13 Recruiting Carvedilol Post-intervention Long-term Administration in Large-scale Trial
Condition: Myocardial Infarction
Interventions: Drug: Carvedilol;   Drug: No Carvedilol
Outcome Measures: All cause mortality;   Composite of death, myocardial infarction, acute coronary syndrome, heart failure hospitalization;   Cardiac death;   Sudden cardiac death;   Cardiovascular death;   Myocardial infarction;   Acute coronary syndrome;   Sustained ventricular tachycardia or ventricular fibrillation;   Heart failure hospitalization;   Stent thrombosis;   Target-vessel revascularization;   Clinically-driven target-lesion revascularization;   Any coronary revascularization;   Any clinically-driven coronary revascularization;   Coronary artery bypass grafting;   Stroke;   Worsening of angina due to coronary spasm;   Bleeding complications;   Composite of death, myocardial infarction, stroke, acute coronary syndrome, heart failure hospitalization, any coronary revascularization;   Composite of cardiac death, myocardial infarction, acute coronary syndrome, heart failure hospitalization;   Composite of cardiovascular death, myocardial infarction, stroke
14 Unknown  Ramipril Versus Carvedilol in Duchenne and Becker Patients
Conditions: Duchenne Muscular Dystrophy;   Becker Muscular Dystrophy
Interventions: Drug: Carvedilol;   Drug: ramipril
Outcome Measures: Left ventricular Ejection Fraction, systolic and diastolic left ventricular volumes and LGE (as a quantitative measure) detected by MRI and myocardial Ultrasound Tissue Characterisation data by Echocardiography.;   Prevalence of LGE in DMD and BMD patients,the effects of pharmacological therapy both on LGE evolution and myocardial UTC analysis.
15 Recruiting Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab
Conditions: Breast Cancer;   Cardiac Toxicity
Interventions: Drug: Coreg CR®;   Drug: lisinopril;   Other: placebo
Outcome Measures: Reduction in incidence of trastuzumab-induced cardiotoxicity after 52 weeks of treatment as measured by preservation of LVEF;   Comparison of the LVEF of each treatment group with the placebo arm;   Number of trastuzumab courses completed without interruption;   Quality-of-life changes as assessed by EORTC-QLQ-C30 questionnaire at baseline and at the end of treatment;   Long-term effects of study drugs as assessed at 18 and 24 months (or 6 and 12 months after completion of trastuzumab therapy)
16 Recruiting Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Carvedilol
Outcome Measures: Incidence of Adverse Events;   Improvement in the six minute walk test (6MWT) and cardiopulmonary exercise testing (CPX);   Improvement in echocardiogram and magnetic resonance imaging (MRI) parameters;   Feasibility of Carvedilol
17 Unknown  Heart Rate Reduction in Heart Failure
Condition: Heart Failure
Interventions: Drug: ivabradine;   Drug: Carvedilol/Ivabradine;   Drug: Carvedilol
Outcome Measures: Exercise tolerance assessed by 6 minute walking test;   Quality of life
18 Recruiting Mechanisms of Increased Ambulatory Blood Pressure in Patients With Intradialytic Hypertension
Condition: Intradialytic Hypertension
Intervention: Drug: Carvedilol vs. Prazosin
Outcome Measures: Ratio of Extracellular Body Water to Total Body Water;   Change in Endothelin-1 from pre to post dialysis
19 Unknown  The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy
Conditions: Duchenne Muscular Dystrophy;   Cardiomyopathies
Intervention: Drug: Carvedilol
Outcome Measures: The suppression of minor cardiac damage indicated as elevation of plasma cTnI;   Left ventricular function deterioration assessed by echocardiography In-hospital mortality for cardiac dysfunction In-hospital mortality for any cause Overall mortality
20 Recruiting Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Carvedilol
Outcome Measures: Absolute change in right ventricular ejection fraction;   right ventricular end systolic volume;   6 minute walk distance;   tricuspid annular plane systolic excursion

These studies may lead to new treatments and are adding insight into Carvedil etiology and treatment.

A major focus of Carvedil research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Carvedil